Sooner or later something has to give for Gilead, and recent share price behavior suggests the protracted dip in its stock price may be turning around. It just... Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
I am putting the brakes on our position in Delphi Automotive after getting a great ride in this stock, and our 73% annualized gain proves it! Read More
We opened this position five weeks ago ago at an entry price of $22.65, so even though we are selling it short of our target price of $28.00 we will still achieve an annualized return in excess of 100% at today's opening price. Read More
Cintas (CTAS) is a stock that I think is at risk of declining in value soon so the appropriate trade would be either a short sale of the stock or an opening purchase of a long put, but DO NOT GO LONG! Read More
With the next FOMC meeting coming this Tuesday/Wednesday, I am holding off on issuing a new buy alert until after they make an announcement regarding the fed funds rate. I am also bumping up the stop price on DLPH to $69, and on BKE to $25. Read More
We are bailing out of LeMaitre Vascular a month early to protect our gain given recent technical weakness in this stock. We have come close to achieving our target return of 20% on an absolute basis (+17% as of yesterday), and on annualized basis we still have a 100% return in this position so I want to lock that in while we can still have it. Read More
During an “Investor Day” presentation to Wall Street analysts this morning in Manhattan, Argos Therapeutics (ARGS) confirmed that the critical ADAPT-3 trial for its AGS-003 cancer immunotherapy treatment is on schedule and appears headed for commercial use in the near future. The company announced two developments that suggest this… Read More
- December 6, 2016
-
Download Issue
It’s hard to perform better than LeMaitre Vascular (LMAT) has been doing lately. In October it reported record sales and increased guidance for the remainder of the year, and last month it made an acquisition that is projected to be immediately accretive to both revenue and earnings. Although LeMaitre’s… Read More
- December 6, 2016
-
Download Issue
Since adding The Buckle (BKE) to our portfolio on Nov. 10, its share price has appreciated more than 10% over our buy limit, even though its quarterly earnings report released one week later came in below expectations. The company reported third-quarter profits of 48 cents per share, three pennies shy… Read More
- December 6, 2016
-
Download Issue
It’s too early for retail analysts to determine what type of holiday season this is going to be for Michael Kors (KORS), which primarily sells higher-priced women’s apparel. The company aggressively matched discounts offered by its rivals over the Black Friday weekend, calling into question the profitability of those sales… Read More